| License: Creative Commons Attribution Non-commercial No Derivatives 4.0 PDF - Published Version (4MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-440692
- DOI to cite this document:
- 10.5283/epub.44069
Mustroph, Julian 
; Drzymalski, Marzena ; Baier, Maria ; Pabel, Steffen ; Biedermann, Alexander ; Memmel, Bernadette ; Durczok, Melanie ; Neef, Stefan ; Sag, Can Martin ; Floerchinger, Bernhard ; Rupprecht, Leopold ; Schmid, Christof ; Zausig, York ; Bégis, Guillaume ; Briand, Veronique ; Ozoux, Marie‐Laure ; Tamarelle, Dorothee ; Ballet, Veronique ; Janiak, Philip ; Beauverger, Philippe ; Maier, Lars S. ; Wagner, Stefan
; Drzymalski, Marzena ; Baier, Maria ; Pabel, Steffen ; Biedermann, Alexander ; Memmel, Bernadette ; Durczok, Melanie ; Neef, Stefan ; Sag, Can Martin ; Floerchinger, Bernhard ; Rupprecht, Leopold ; Schmid, Christof ; Zausig, York ; Bégis, Guillaume ; Briand, Veronique ; Ozoux, Marie‐Laure ; Tamarelle, Dorothee ; Ballet, Veronique ; Janiak, Philip ; Beauverger, Philippe ; Maier, Lars S. ; Wagner, Stefan 
Abstract
Aims Excessive activation of Ca/calmodulin-dependent kinase II (CaMKII) is of critical importance in heart failure (HF) and atrial fibrillation. Unfortunately, lack of selectivity, specificity, and bioavailability have slowed down development of inhibitors for clinical use. We investigated a novel CaMKII delta/CaMKII-selective, ATP-competitive, orally available CaMKII inhibitor (RA608) on right ...
Owner only: item control page
Download Statistics